Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| No statute on record | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MARIANNE P | 2 | 59.8% | +18.5% |
| SWIFT, CANDICE LEE | 1 | 58.3% | +38.5% |
| ALLEN, MICHAEL D | 1 | 32.6% | +48.7% |
| MEYERING, SHABANA SHABBEER | 1 | 71.2% | +37.8% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 334d overdue |
| 17815468 | Lysosomal Targeting Peptides and Uses Thereof | ALLEN, MARIANNE P | 38d overdue |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | ALLEN, MARIANNE P | 38d overdue |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | ALLEN, MICHAEL D | 22d overdue |
| 18573298 | COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF | SWIFT, CANDICE LEE | 4d overdue |
| 18311789 | METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY | MEYERING, SHABANA SHABBEER | 26d |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1657 | 1 |
| 1671 | 1 |
| 1635 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573298 | COMPOSITIONS OF BETA-HEXOSAMINIDASE VARIANTS AND USES THEREOF | SWIFT, CANDICE LEE | 1657 | §103 | Non-Final OA | 4d overdue | Pending | Dec 21, 2023 |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | 22d overdue | Pending | Jul 20, 2023 |
| 18311789 | METHOD OF TREATING DUCHENNE MUSCULAR DYSTROPHY | MEYERING, SHABANA SHABBEER | 1635 | Other | Non-Final OA | 26d | Pending | May 03, 2023 |
| 17815468 | Lysosomal Targeting Peptides and Uses Thereof | ALLEN, MARIANNE P | 1647 | §103 | Non-Final OA | 38d overdue | Pending | Jul 27, 2022 |
| 17829620 | Lysosomal Targeting Peptides and Uses Thereof | ALLEN, MARIANNE P | 1647 | §103 | Non-Final OA | 38d overdue | Pending | Jun 01, 2022 |
| 17634034 | Hydrophobic Peptide Salts for Extended Release Compositions | REYNOLDS, FRED H | 1658 | Other | Non-Final OA | 334d overdue | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial